Description:
This plenary session is composed of a panel of representatives for addressing responses to business disruption in the pharmaceutical industry. Panelists will discuss approaches used to address COVID-19 disruptions and other emergency cases with an eye towards lessons learned for building greater business resilience. Topics span discovery, manufacturing, supply chain, regulatory practices and remote work.
Sponsor:
Pharmaceutical Discovery, Development and Manufacturing Forum
Chair:
Kevin D. Seibert
Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, IN
Co-Chair:
Andreas Bommarius
School of Chemical & Biomolecular Engineering, Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA
Abstract Submissions Closed
See more of this Group/Topical: Pharmaceutical Discovery, Development and Manufacturing Forum